Krystal Biotech (KRYS) Long-Term Investments (2019 - 2026)

Krystal Biotech has reported Long-Term Investments for 7 years, with the latest figure at $257.3 million in Q2 2026.

• Long-Term Investments for Q2 2026 came in at $257.3 million, up 85.36% year-over-year; the trailing twelve-month figure through Jun 2026 was $257.3 million (up 85.36% YoY), and the FY2025 annual result was $128.1 million, down 15.81% from the prior year.
• Long-Term Investments improved to $257.3 million in Q2 2026, from $193.5 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $257.3 million in Q2 2026 and troughed at $4.6 million in Q4 2022.
• A 5-year average of $89.2 million and a median of $76.6 million in 2024 frame the typical range for Long-Term Investments.
• The widest annual swing landed in 2022, when Long-Term Investments plunged 92.82%; it then soared 1537.67% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $4.6 million in 2022, then surged by 1240.71% to $62.0 million in 2023, then soared by 145.53% to $152.1 million in 2024, then dropped by 15.81% to $128.1 million in 2025, then surged by 100.91% to $257.3 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $257.3 million in Q2 2026, $193.5 million in Q1 2026, and $128.1 million in Q4 2025.